GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET
Company Participants
Gabrielle DeGravina - CG Capital
David Dodd - Chairman, President & CEO
Mark Reynolds - CFO
Kelly McKee - Chief Medical Officer
Mark Newman - Chief Scientific Officer
John Sharkey - Head of Business Development
Conference Call Participants
Jason Kolbert - Dawson James Securities
Vernon Bernardino - H.C. Wainwright & Co.
Joanne Lee - Maxim Group
Robert LeBoyer - Noble Capital
Kumar Raja - ROTH Capital
Jeffrey Kraws - Crystal Research Associates
Operator
Good afternoon and welcome everyone to the GeoVax Fourth Quarter and Full Year 2022 Corporate Update Call. My name is Diego and I will facilitate today's call. With me today are David Dodd, Chairman and CEO; Mark Reynolds, Chief Financial Officer; Mark Newman, Chief Scientific Officer; Dr. Kelly McKee, Chief Medical Officer; and Dr. John Sharkey, Vice President, Business Development. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please note, this event is being recorded.
I’ll now turn the conference over to our host, Gabbie DeGravina of CG Capital. Thank you. You may begin.
Gabrielle DeGravina
Thank you. Please note the following. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.
Actual results may differ materially from those included in these statements due to a variety of factors, including whether GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner. GeoVax's vaccines will be safe for human use. GeoVax's vaccines will effectively prevent targeted infections in humans. GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed.
GeoVax raises required capital to complete vaccine development. There is development of competitive products that maybe more effective or easier to use in GeoVax's products. GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors over which GeoVax has no control.
GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission, including those set forth at risk factors in GeoVax's Form 10-K.
It is now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd.